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Summary
Escherichia coli hemolysin, a transmembrane pore-forming exotoxin, is considered an important
virulence factor for E . coli-related extraintestinal infections and sepsis. The possible significance
of hemolysin liberation for induction ofinflammatory lipid mediators was investigated in isolated
rabbit lungs infused with viable bacteria (concentration range, 104-10'/ml) . Hemolysin-secreting
E . coli (E. coli-Hly+), but not an E . coli strain that releases an inactive form of the exotoxin,
induced marked lung leukotriene (LT) generation with predominance of cysteinyl Us . Eicosanoid
synthesis was not inhibited in the presence ofplasma with toxin-neutralizing capacity . Pre-application
of 2 x 108 human granulocytes, which sequestered in the lung microvasculature, caused a
severalfold increase in leukotriene generation in response to E. coli-Hly+ challenge both in the
absence and presence of plasma. Data are presented indicating neutrophil-endothelial cell cooperation
in arachidonic acid lipoxygenase metabolism as an underlying mechanism . We conclude that
liberation of hemolysin from viable E . coli induces marked lipid mediator generation in lung
vasculature, which is potentiated in the presence of neutrophil sequestration and may contribute
to microcirculatory disturbances during the course of severe infections .
Approximately 50% ofEscherichia coli isolates causing extra-
intestinal infections in man elaborate a proteinaceous
hemolysin, which thus represents one of the most prevalent
bacterial exotoxins encountered in humans (1-5) . The rele-
vance ofthis hemolysin as a determinant ofbacterial pathoge-
nicity has been established in animal models with the use
of genetically engineered, isogenic bacterial strains (6, 7) . An
analogous role in human infection has been inferred from
the high association of hemolysin production with disease,
including pyelonephritis and septicemia (2, 3) . The hemolysin
was characterized as a novel prototype of a pore-forming pro-
tein that may insert as a monomer into target lipid bilayers
to generate a functional transmembrane lesion of 1-2 nm efFec-
tive diameter (8-10) . Structurally related toxins are also pro-
duced by other Gram-negative rods including Morganella,
Proteus, and Pasteurella haemolytica . These agents constitute
a family of protein toxins with similar functional and im-
munological properties (11-13) .
Granulocytes have been identified as preferred target cells
forE . coli hemolysin inhuman blood, and the exotoxin turned
out as most potent leucocidin known to date (14) . In addi-
tion, intravascular application ofthe hemolysin in blood-free
perfused rabbit lungs revealed high sensitivity of the pulmo-
nary microvasculature to this bacterial agent (15) . Key events
of acute respiratory failure were evoked, hallmarked by
thromboxane-mediated pulmonary hypertension and sustained
vascular leakage with progressive lung edema formation . These
biophysical alterations were preceded by a burst ofinflamma-
tory lipid mediator generation, in particular, release of leu-
kotrienes (16) . These findings may be of clinical relevance
as bacterial sepsis is the most consistent factor associated with
the development of acute respiratory failure in adults, with
Gram-negative rods, includingE. coli, currently representing
the predominant infectious agents (17, 18) .
In physiological environments, including plasma constit-
uents and granulocytes, the capacity of hemolysin-secreting
E. coli to evoke lung microvascular disturbances may possibly
be limited due to the presence of hemolysin-inactivating pro-
teins (e.g., naturally occurring antibodies, lipoproteins [14))
and rapid bacterial phagocytosis. Based on this reasoning, we
conducted a study on the interaction ofhemolysin-secreting
viable E . coli with the vasculature of isolated rabbit lungs,
perfused both in the absence or presence of plasma and gran-
ulocytes . Acute pulmonary hypertension and protracted lung
vascular leakage were again noted, corresponding to the effects
of the isolated hemolysin (W Seeger et al ., manuscript in
preparation) . In the present communication, we report on
marked lipid mediator generation elicited by the exotoxin-
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was even augmented in the presence of plasma and granulo-
cytes, and cumulative evidence suggests cooperative eicosa-
noid synthesis occurring upon in situ hemolysin challenge
of endothelium-adherent granulocytes .
Materials and Methods
Reagents . The leukotrienes (Us)' LTC4, LTD4, LTE4, and
LTB4, 20-OH- and 20-COON-LTB4, and the synthetic LTA4-
methyl ester were a generous gift from Dr. J. Rokach, Merck Frosst,
Canada . 5-, 8-, 9-, 11,- 12-, and 15-hydroxyeicosatetraenoic acid
(HETE), as well as 5S.12S-diHETE, 5.15-diHETE, and 12-HHT,
were obtained from Paesel AG, Frankfurt, FRG . All Us were
checked for purity and quantified spectrophotometrically before use
as described (19) . TritiatedUs,used as internal standards, were ob-
tained from New England Nuclear, Dreieich, FRG. Chromato-
graphic supplies included HPLC-grade solvents, distilled in glass
(Fluky KG, Heidelberg, FRG), octadecylsilyl 5-pm (Hypersil), and
silica gel 5-jm column packing (Machery-Nagel, Duren, FRG),
and C-18 Sep-pack cartridges (Waters Associates, Milford, MA) .
Anti-LTB4 antiserum was received from Dr.J . Salmon (Wellcome
Research Laboratories, Beckenham, UK), and anti-LTC4 antiserum
was from NewEngland Nuclear. D,L-Lysin-monoacetylsalicylate/
glycin (9:1) was obtained from Bayer AG (Leverkusen, FRG), and
BSA (96% purity, reduced in FFA to <5 lAg/g) was from Paesel
AG (Frankfurt, FRG) . All other biochemicals were obtained from
Merck AG (Darmstadt, FRG) in pro-analysis quality.
Isolated Lung Model .
￿
The model hasbeen previously described
(15, 20-22) . Briefly, rabbits of either sex (body weight, 2.2-2.6
kg) were deeply anesthetized and anticoagulated with 1,000Uof
heparin per kilogram body weight . The lungs were excised while
being perfused with Krebs Henseleit albumin buffer (KHAB)
through cannulas in thepulmonary artery and the left atrium . The
buffer contained 132.8 mM NaCl, 4.3 mM KCI, 1.1 mM
KH2P04, 24 .1 mM NaHC03 , 2.4 mM CaCIZ, and 1.3 mM
(Mg)3(PO4)x, as well as 240 mg glucose and 1 g albumin per 100
ml . The lungs were placed in a temperature-equilibrated housing
chamber at 37°C, freely suspended from a force transducer. They
were ventilated with 4% C02 , 17% 02, and 79% N2, and the
pH ofthe perfusion fluid ranged between 7.35 and 7.45 . After ex-
tensive rinsing of the vascular bed, the lungs were recirculatingly
perfused with a pulsatile flow of 100 ml/min . The alternate use
oftwo separate perfusion circuits, each containing 200ml, allowed
exchange ofperfusion fluid . The left atrial pressure was set 2 mmHg
under baseline conditions (0 referenced at the hilum) to guarantee
zone III conditions at end-expiration throughout thelung. Lungs
selected for the study were those that : (a)had a homogenous white
appearance without signs of hemostasis or edema formation ; (b)
hadpulmonary artery and ventilation pressures in the normal range ;
and (c) did not exhibit spontaneous weight gain during a steady-
state period of 40 min . Absence of circulating cells in the lung
effluent was ascertained in each experiment .
Preparation of Human Granulocytes and Rabbit Plasma.
￿
Hepari-
nizedhumandonorbloodwas centrifuged in adiscontinuous Per-
coil gradient (23, 24) to yield a PMN fraction of -97% purity.
The granulocytes were kept in RPMI 1640 with 20% calf serum
for 90-120 min. Immediately before use, the cells were washed twice
t Abbreviations used in thispaper . AA, arachidonic acid; ASA, acetylsalicylic
acid ; HETE, hydroxyeicosatetraenoic acid;KHAB, Krebs Henseleit albumin
buffer ; LT, leukotriene .
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andsuspended inKHAB. Rabbit bloodwasobtained from anesthe-
tized animals by femoral artery catheterization after anticoagula-
tion with heparin. Blood was centrifuged for 10 min at 3,000 g,
and plasma was stored at -70'C until experimental use.
Preparation ofE . coli.
￿
A hemolysin-producing E. coli strain
(LE2001; Hly') and anE. coli strain secreting an inactive form of
the toxin (MC4100; Hly -) (25) were used. Both strains were
grown to late logarithmic phase, washed three times in KHAB
(3 min, 690 g), and quantified by absorbance measurement at 578
nm. Acalibration curve established for eachE . coli strain wasused .
Based on this approximate quantification, aliquots of the E. coli
suspension were mixedwith thelung buffer medium directly after
the final washing procedure to achieve the required bacterial con-
centrations . Aliquots were plated on agar, andCFUwere counted
for definitive quantification in each experiment . Data evaluation
wasundertaken only when the approximate quantification differed
from counts by <30% .
Analytical Procedures.
￿
Us andHETEswere extractedfrom lung
perfusion fluid by octadecylsilyl solid phase extraction columns as
described (19, 26). Conversion into methylesters was performed
by addition offreshlyprepared diazomethan in ice-cold diethyl ether.
Reversed-phase (RP)-HPLC of nonmethylatedcompoundswas car-
ried outon octadecylsilyl columns (Hypersil ; 5-,um particles) with
a mobile phase of methanol/water/acetic acid (72:28:0.16, pH 4.9
[19]) . In addition to the conventional UV detection at 270nm (Us)
and 237 nm (HETEs), a photodiode array detector (990; Waters
Associates) wasused that provided fullUV spectra (190-600 nm)
of eluting compounds and allowed checking for peak purity and
substraction ofpossible coeluting material . For further verification,
samples were collected in 15-s fractions and subjected to post-HPLC-
RIA with anti-LTC4 and anti-LTB4 as described (19, 26). RP-
HPLC of methylated compounds was performed isocratically
(72:28:0.16, pH 4.9) for 5 min, followed by a linear gradient to
90:10:0.16 over 10 min (gradient former model 250 ; Gynkothek,
Munich, FRG) . Single-phase (SP)-HPLC was carried out using a
modification ofthemethod of Powell (27) . Isocratical elution with
hexane/isopropanol/acetate (97:3:0 .1 ; 12 min) was followed by a
linear gradient to 86:14:0 .1 over 10 min. All data obtained by the
different analytical procedures were corrected for the respective recov-
eries ofthe overall analytical procedure and are given in nanomoles
per total perfusate volume. Recovery was determined by separate
recovery experiments using different quantities of the individual
compounds in the appropriate concentration range . Factors for
recovery were further confirmed by addition of 40-80 t.Ci [3H]
LTC4, ['H]LTB4, and ['H]5-HETE to the perfusate as internal
standards in selected samples. Detection limits of the differentcom-
pounds are indicated in Table 2 .
E. coli hemolysin concentrations in the buffer fluidwere deter-
mined by an ELISA that uses a monoclonal anti-hemolysin anti-
body to capture the antigen, and a second, polyclonal antibody
for development, as described (28) .
ExperimentalProtocol.
￿
After a steady-state period of40 min, the
recirculatingperfusate wasexchangedby fresh buffer medium,which
contained 500,,M acetylsalicylic acid (ASA) in all experiments . This
cyclooxygenase inhibitor was used to suppress hemolysin-evoked
severe pulmonary hypertension, known to be mediated predomi-
nantly by lung thromboxane generation (15) . In particular experi-
ments, theKHAB perfusatewas supplemented with 15% (vol/vol)
rabbit plasma . Human plasma cannot be used in perfused rabbit
lung studies, as its complement system is known to be activated
spontaneously at rabbit cell surfaces via the alternate pathway (29,
30) . Higher percentages of rabbit plasma were not used because
of analytical limitations of the chromatographic techniques arising
Hemolysin-Forming Escherichia coli and Lung Leukotriene Generationunder these conditions. 10 min after perfusate exchange, 2 x 108
PMN in 2 ml KHAB or thesame volume ofcell-free buffer were
slowly injected into the pulmonary artery. Random cell counts in
the recirculating medium 3 and 10 min after PMN application
documented a nearly quantitative sticking ofthese cells in the lung
vasculature (<3% circulating PMN) . Microscopical examinations
revealed that the vast majority of the PMN were sequestered in
the pulmonary capillaries . This is in line with previous investiga-
tions, in which >90% of freshly prepared PMN were noted to mar-
ginate in alveolar microvessels after bolus application in isolated
perfused lungs (31-33) . 10 min after PMN or sham application,
liveE. coli bacteriae were admixed to the recirculating buffer volume
to give final concentrations of 10 4 , 10 5 , 106 , or 10' CFU/ml; and
time was set as zero. 10-ml perfusate samples for determination
of arachidonic acid (AA) lipoxygenase products were taken at -2,
5, 10, 20, 30, 60, and 90 min (end of experiment) . Samples were
immediately centrifuged at 0°C (5,000 g, 5 min) and kept on ice
until transfer to the extraction columns.
In parallel with each lung experiment in which granulocytes
were applied, six, aliquots of 4 x 106 PMN (corresponding prep-
aration) were suspended in a total volume of 5 ml buffer fluid, com-
posed in analogy to thelungperfusate(KHAB orKHAB plus rabbit
plasma) . According to the time schedule ofthelung experiments,
the incubation wasterminated after 5, 10, 20, 30, 60, and 90 min,
respectively, by centrifugation at 0°C (5,000 g, 5 min) . The total
5-ml supernatant was subjected to eicosanoid analysis .
Control experiments, following an identical time schedule but
performed in the absence ofE . coli, included lung perfusions with
buffer, buffer plus rabbit plasma, buffer plus PMN, or buffer plus
rabbit plasma plusPMN (for each, n = 2) . Corresponding in vitro
incubations ofPMN in the absence ofE. coli were performed. In
additional controls, 106/ml nonhemolytic E. coli (E . coli-Hly- )
were applied using the same protocols .
Control experiments for determination of the disappearance rate
(metabolism/uptake) ofindividual LTs and 5-HETE in the isolated
lung preparation were performed by use ofradiolabeled standards
(Table 1) . Concentrations used were those corresponding to the
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range of LTs and 5-HETE appearing in the model of pulmonary
leukostasis.
Results
Lung Perfusion with E . coli-Hly+ in the Absence ofPMN .
Under baseline conditions, AA lipoxygenase products in lung
perfusates ranged below the detection limits of the respec-
tive analytical procedures . Application of viable E. coli-Hly+
elicited a dose-and time-dependent release ofeicosanoids into
the recirculating buffer medium (Figs . 1-6), commencing
within 5-10 min after bacterial challenge, with cysteinyl LTs
representing the quantitatively dominating compounds. The
time course of LTC4 liberation (rapid onset, followed by sub-
sequent decline) vs . that ofLTE4 appearance (delayed onset,
plateauing after 30-60 min) suggested metabolism of LTC4
via LTD4 to LTE4 . These metabolic steps have been demon-
strated for perfused lungs of different species, including the
rabbit (19, 21, 34) . The very rapid conversion of LTD4 to
LTE4 is responsible for low perfusate levels of the former,
ranging below or just above the respective detection limit
(LTD4 data not given in detail) . In addition to the cysteinyl
LTs, LTB4 appeared in the buffer medium of E . coli-Hly+-
challenged lungs. This compound displayed similar time course
(plateau after 30-60 min) but lower total amount as com-
pared with the cysteinyl LTs . No w oxidation products of
LTB4 appeared in these experiments performed in the ab-
sence of infused granulocytes . This lack ofLTB4-20 hydrox-
ylation has previously been noted (19, 21) . It is explainedby
the relatively lowquantities of marginatedPMN in this blood-
free perfused lung model, and by the virtual absence of w
oxidation capacity of rabbit (F. Grimminger et al ., unpub-
lished data) and porcine (35) PMN, a finding that contrasts
with that of human neutrophils (36) .
Table 1 .
￿
Disappearance Rate of Radiolabeled AA Lipoxygenase Products from the Pulmonary Circulation
Radiolabeled standards (15 nmol LTC4 and LTB4; 5 amol 5-HETE, 6-trans-LTB4, and 6-trans-epi-LTB4) were bolus injected into the pulmonary
artery ofKHAB-perfused rabbit lungs under baseline conditions . The recoveries from the perfusate at the different times after application are indicated
(mean [SE] of five independent experiments) .
" In blood-free perfused rabbit lungs without pre-application of human PMN, LTB4 is not w oxidized (24) . Metabolites of LTB4 do thus not need
to be considered for calculation of recovery under these conditions .
Injected 'H standard 5 min
Recovery
30 min
from the perfusate
55
at :
min 95 min
min
LTC4 + metabolites
(LTD4 and LTE4) 84.2 (2.9) 74.9 (3.2) 62 .1 (4.3) 50.9 (5.3)
LTB4 77.4 (5.4) 54.6 (4.4) 43 .5 (3.8) 32 .2 (4.9)
5-HETE 80.8 (8.4) 44.9 (4.1) 21 .3 (2.4) 11 .7 (0.9)
6-trans-LTB 4 85.2 (2.9) 70.4 (5.2) 58.4 (4.2) 48 .5 (6.1)
6-trans-epi-LTB4 82.8 (2.1) 64.9 (3.8) 54.0 (2.8) 44.5 (4.8)3,
2-
0
7-
6
5-
4-
3-
2-
1
0
L TB, (nmol)
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￿
60
￿
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(min)
Figure 1 .
￿
Time-dependent liberation of eicosanoids into the buffer me-
dium of lungs and/or PMN challenged with 106/ml E. coli-Hly* . Lungs
(Lu) were perfused with 200 ml KHAB in the absence or presence of
rabbit plasma (Pla ; 15% [vol/vol]) and human PMN (2 x 108) . Total
amounts of the different AA lipoxygenase products in the recirculating
perfusate volume are given. In accompanying in vitro experiments, 5 x
106 PMN were incubated with 106/ml E. coli-Hly " in a buffer volume
of 5 ml ; total amounts of eicosanoids measured in these studies were cor-
rected (factor 40) to correspond to the buffer volume in the perfused lung
experiments, 20-OH-LTB4 and 20-COOH-LTB4 are comprised as w ox-
idation products (w-ox) of LTB4 . The LTA4 hydrolysis products include
the 5,6-diastereomeric pair of LTB4, both nonenzymatically formed
5,6-diHETEs. Means offour independent experiments are given for each
group and each time point . SEM data are included in Table 2 .
w- ox LTB4 (nmol)
Figure 2 .
￿
See Fig. 1.
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See Fig . 1 .
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PMN.Pla-LTA4 hydrolysis products
PMN .Pla-5-HEM
60 90
(min)
All eicosanoids formed in the E. coli-Hly+-challenged
lungs (Table 2), as well as the total sum ofAA lipoxygenase
products (Fig . 6), displayed corresponding dose dependency.
Lipid mediator formation was not detectable at 104 bac-
teria/ml, commenced at 105/ml, and plateaued at 106-10'/ml .
In contrast to the leukotrienes, no 5-, 8-, 9-, 11-, 12-, or
15-HETEs, di-HETEs (5S.12S- or 5.15-), or nonenzymatic
degradation products of LTA4 were detected . Due to the
presence ofASA in all experiments, liberation of thromboxane
AZ and prostaglandin I Z ranged below detection limits
(random measurements with RIA in lung perfusate) . The
presence of rabbit plasma did not affect profile, time course,
0 10 20 30
￿
60
￿
90
(min)Figure 5 .
￿
See Fig. 1 .
15~
to-
5-
0 10 20 30
￿
60
￿
90
(min)
and amount of AA lipoxygenase product formation (Lu +
Pla in Figs . 1-6) . A dose-dependent liberation of hemolysin
into the buffermedium was documented byELISA (Table 3) .
E. coli-Hly+ Challenge in the Presence ofPMN.
￿
Incuba-
tion ofPMN withE. coli-Hly+ in vitro induced rapid gener-
a
20-1 F AA Lipoxy genase Products (nmol)
(30min )
Lu .Pla
Lu
--__--0 PMN
104 105 106 107
E. coli -Hly*/ml
Figure 6 .
￿
Total sum ofAA lipoxygenase products measured in perfused lung and isolated PMN experiments 30 and 90 min after challenge with
the different concentrations of E. coli-Hly+ . Experimental conditions and abbreviations correspond to those in Figs. 1-5 . Each point represents mean
of four independent experiments .
1119
￿
Grimminger et al.
ation of LTBa, peaking after 20 min . It was accompanied
and followed by a more delayed appearance of20-OH- and
20-COOH-LTBa, combined as w oxidation products in Fig.
2 and Table 2, in accordance with the known w oxidation
capacity of human PMN (36) . In parallel with LTB4 gener-
ation, substantial amounts of 6-trans- and 6-trans-epi-LTBa,
as well as 5.6-diHETEs, were detected in the incubation
medium . These products indicate secretion of intact LTA4
into the extracellular space ; they are comprised as nonen-
zymatic LTA4 hydrolysis products in Fig. 3 and Table 2 . All
AA lipoxygenase products displayed corresponding dose de-
pendency. Release reaction commenced at 105 bacteria/ml
and plateaued at 106-101 ml . 5-HETE ranged just above the
detection limit in single experiments performed with the
higher bacterial load. Cysteinyl LTs were not measured upon
PMN challenge in vitro, indicating absence of significant
amounts of eosinophils in the granulocyte preparation . 12-
HETE, 5S,12S-DiHETE, and 15-HETE all ranged below de-
tection limits, indicating absence of contaminating platelets
and lymphocytes . The admixture of rabbit plasma to PMN
incubated with E.'coli-Hly+ in vitro did not alter profile and
time course of AA lipoxygenase product formation . How-
ever, all LTA4-derived enzymatic and nonenzymatic products
ranged at two- to threefold higher values in the presence of
opsonin .
Infusion of E. coli-Hly+ in rabbit lungs, in which 2 x
10 8 human PMN were sequestered, again elicited predomi-
nant cysteinyl IT generation, with profile and time course
(early LTC4 release, protracted LTE4 accumulation) corre-
Y AA Lipoxy genase Products (nmol)
20 n
f0 ~
5-
(90min )
104 105 106 107
E. coti-My '/mlTable 2.
￿
Generation ofEicosanoids in E . Coli-HLY*-challenged Perfused Lungs and PAIN In Vitro
sponding to the findings in non-PMN-charged lungs . Ac-
companying LTB4 generation was again noted . However, in
contrast to the experiments without preceding PMN appli-
cation, substantial amounts ofw oxidation products ofLTB4
appeared, indicating integer LTB4 metabolizing capacity of
the sequestered human granulocytes. Nonenzymatic hydro-
lysis products of LTA4 and 5-HETE were not detected.
Profile and time course of eicosanoid liberation were iden-
tical in the presence ofboth PMN and rabbit plasma. Notably,
however, both maneuvers caused a marked increase in the total
amounts of AA lipoxygenase products. In the presence of
PMN, an approximately two- to threefold augmentation was
noted at all concentrations of bacteria used (10 5/ml), and
the preceding application of both plasma and PMN in the
perfused lungs resulted in an approximately fivefold increase
in leukotriene generation in response to E. coli-Hly+ chal-
lenge. The hemolysin concentrations detected in the lung per-
fusate in the presence of PMN did not substantially differ
from those measured in the absence ofgranulorytes (Table 3) .
Control Studies.
￿
In the absence of plasma or PMN, the
E. coli strain producing inactive hemolysin (Hly - ; used at
106/ml) did not induce any measurable liberation of AA
lipoxygenase products both in the perfused lung experiments
and in the isolatedPMN studies. In the presence ofboth plasma
and PMN, eicosanoid liberation occurred with profiles cor-
responding to those evoked by E . coli-Hly+ (Table 4) . The
total amounts of the different lipoxygenase products were,
however, only -30% of those evoked by challenge with the
corresponding concentration of E. coli-Hly+ .
In all control studies using plasma, PMN, or both in the
absence ofE. coli, no measurable lipoxygenase product for-
mation was noted in the isolated lungs and upon PMN incu-
bation in vitro .
Discussion
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continued
In a preceding study in isolated rabbit lungs, bolus appli-
cation of purifiedE . coli hemolysin (250 ng/ml perfusate)was
LTA4 hydrolysis 5-HETE LTC4 LTE4
30 min 90 min 30 min 90 min 30 min 90 min 30 min 90 min
<0 .1 <0 .1 <0.15 <0.15 <0 .2 <0 .2 <0.2 <0.2
<0 .1 <0 .1 <0.15 <0.15 <0 .2 <0 .2 <0.2 <0.2
<0 .1 <0 .1 <0.15 <0.15 <0 .2 <0 .2 <0.2 <0.2
<0.1 <0 .1 <0.15 <0.15 <0.2 <0 .2 <0.2 <0.2
<0 .1 <0 .1 <0.15 <0.15 <0.2 <0 .2 <0.2 <0 .2
<0 .1 <0 .1 <0.15 <0.15 <0.2 <0.2 <0.2 <0 .2
<0 .1 <0 .1 <0.15 <0.15 0.24 <0 .2 0.61 1.35
± 0.09 ± 0.22 ± 0.32
<0 .1 <0 .1 <0.15 <0.15 <0.2 <0.2 1 .02 1.64
± 0.31 ± 0.30
<0 .1 <0.1 <0.15 <0.15 0.48 <0.2 1 .01 2.86
± 0.12 ± 0.24 ± 0.41
<0 .1 <0 .1 <0.15 <0.15 0.99 0.31 2 .23 3.28
± 0.28 ± 0.12 ± 0.44 ± 0.68
<0 .1 <0 .1 <0.15 <0.15 <0 .2 <0.2 <0.2 <0.2
0.29 0.31 0.31 <0.15 <0 .2 <0 .2 <0.2 <0.2
± 0.05 ± 0.06 ± 0.10
<0 .1 <0 .1 <0.15 <0.15 0.46 0.28 1.22 2.53
± 0.16 ± 0.11 ± 0.31 ± 0.41
<0 .1 <0 .1 <0.15 <0.15 0.31 <0 .2 1.35 2.41
± 0.10 ± 0.26 ± 0.62
<0 .1 <0 .1 <0.15 <0.15 1 .05 0.34 2.48 5.13
± 0 .31 ± 0.11 ± 0.51 ± 0.92
E . coli/ml Protocol
LTB4
30 min 90 min
20-ox-LTB4
30 min 90 min
104 Lu <0.1 <0.1 <0 .1 <0 .1
Lu + Pla <0.1 <0.1 <0 .1 <0 .1
Lu +PMN <0 .1 <0.1 <0 .1 <0 .1
Lu +PMN+ Pla <0 .1 <0 .1 <0 .1 <0 .1
PMN <0 .1 <0 .1 <0 .1 <0 .1
PMN+ Pla <0 .1 <0 .1 <0 .1 <0 .1
105 Lu 0.59 <0 .1 <0.1 <0 .1
± 0.13
Lu + Pla <0.61 <0 .1 <0 .1 <0 .1
± 0.21
Lu + PMN 0.69 0.31 0.66 2.13
± 0.12 ± 0.12 ± 0.21 ± 0.41
Lu +PMN + Pla 0.88 0.56 1.13 3.02
± 0.31 ± 0.22 ± 0.25 ± 0.55
PMN <0 .1 <0.1 <0 .1 0.46
± 0.14
PMN + Pla 0.59 0.31 1 .13 1.94
± 0.13 ± 0.08 ± 0.28 ± 0.21
106 Lu 1.21 0.34 <0 .1 <0 .1
0.32 ± 0.12
Lu+ Pla 0.96 0.27 <0 .1 <0 .1
± 0.24 ± 0.13
Lu +PMN 1 .44 0.6 2 .31 3.78
±0.41 ±0.20 ±0 .38 ±0.51Table 2. (continued)
E . coli/ml
Lungs (Lu) were perfused with 200 ml KHAB in the absence or presence of rabbit plasma (Pla; 15% [vol/vol]) and humanPMN (2 x 108) . They
were challenged with different concentrations ofE . coli-Hly+ in the buffer medium . Total amounts of the various AA lipoxygenase products in
the perfusate medium 30 and90 min after application of the bacteria are given in nanomoles . In accompanying in vitro experiments, 5 x 10 6 PMN
were incubated with 106/mlE . coli-Hly+ in a buffer volume of 5 ml; total amounts of eicosanoids measured in these studies were corrected (factor
40) to correspond to the buffer volume in the perfused lung experiments . 20-OH-LTB4 and 20-COOH-LTB4 are comprised as w oxidation products
of LTB4 The LTA4 hydrolysis products include the 5,6-diastereomeric pair of LTB4, both nonenzymatically formed 5,6-diHETEs . Each point
represents mean ± SEM of four independent experiments .
Table 3.
￿
Hemolysin Concentration in the Recirculating Buffer Fluid of Perfused Lungs
Concentration after E . coli (Hly+) application interval of :
E . coli/ml
￿
Protocol
￿
30 min
￿
60 min
￿
90 min
Lungs (Lu) were perfused with 100 ml KHAB in the absence or presence of humanPMN (2 x 108) . They were challenged with different concen-
trations ofE. coli-Hly+ in the buffer medium . Hemolysin was determined in aliquots of the perfusate taken at the indicated intervals after applica-
tion of the bacteria . Measurements in the presence of plasma could not be performed due to nonspecific disturbances in the ELISA . Each point represents
mean ± SEM of four independent experiments .
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Protocol
LTB4
30 min 90 min
20-ox-LTB4
30 min 90 min
LTA4 hydrolysis
30 min 90 min
5-HETE
30 min 90 min
LTC4
30 min 90 min
LTE4
30 min 90 min
Lu+PMN+Pla 2 .82 1.58 2.41 6.82 <0 .1 <0.1 <0.15 <0.15 2.53 1 .32 3.98 7.66
± 0.46 ± 0.32 ± 0.61 ± 1 .04 ± 0.69 ± 0.44 ± 0.92 ± 1.21
PMN 0.41 0.15 0.92 1 .62 <0 .1 <0.1 <0.15 <0.15 <0.2 <0 .2 <0.2 <0.2
± 0.16 ± 0.06 ± 0.24 ± 0.37
PMN+Pla 1 .98 0.49 2.13 3.92 0.69 0.48 0.68 <0.15 <0 .2 <0 .2 <0.2 <0.2
± 0.36 ± 0.21 ± 0.44 ± 0.56 ± 0.28 ± 0.16 ± 0.10
Lu 1 .34 0.51 <0.1 <0 .1 <0 .1 <0 .1 <0.15 <0.15 0.31 <0 .2 0.99 1.68
± 0.42 ± 0.18 ± 0 .14 ± 0.24 ± 0.42
Lu+Pla 1 .84 0.26 <0.1 <0 .1 <0 .1 <0 .1 <0.15 <0.15 <0.5 <0 .2 1.62 2.39
± 0.31 ± 0.11 ± 0.18 ± 0.39 ± 0.51
Lu +PMN 1 .80 0.52 2.59 4.10 <0 .1 <0 .1 <0.15 <0.15 0.62 0.25 2.08 3.96
± 0.44 ± 0.21 ± 0.43 ± 0.56 ± 0.24 ± 0.1 ± 0.41 ± 0.49
Lu +PMN+Pla 2.72 0.66 3.96 9.68 <0.1 <0.1 <0.15 <0.15 2 .08 0.66 4.31 6.49
± 0.54 t 0.16 ± 0.81 ± 1.23 ± 0.51 ± 0.22 ±0.67 ± 0.83
PMN 0.52 0.22 0.83 1.98 <0.1 <0 .1 <0.15 <0.15 <.02 <0.2 <0.2 <0 .2
± 0.13 ± 0.11 ± 0.24 ± 0.41
PMN+Pla 2.43 0.68 2.12 4.61 0.81 0.62 0.81 <0.15 <0.2 <0.2 <0.2 <0 .2
± 0.41 ± 0.21 ± 0.62 ± 0.71 ± 0.21 ± 0.11 ± 0.33
104 (n = 4)
105 (n = 4)
Lu
Lu + PMN
Lu
Lu + PMN
<20
<20
<20
<20
<20
<20
<20
<20
<20
<20
<20
<20
106 (n = 4) Lu 32.5 ± 15 .6 59.0 ± 21.3 63.2 ± 20.2
Lu + PMN 15 .0 ± 5.5 35 .0 ± 7.8 48 ± 14
10' (n = 4) Lu 79.6 ± 41 .3 110.6 ± 38.6 134.4 ± 29.9
Lu + PMN 66.0 ± 24.4 90.4 ± 20.2 117.0 ± 19.6Lungs (Lu) were perfused with 200ml KHAB in the absence or presence of rabbit plasma (Pla ; 15% [vol/volt) and human PMN (2 + 108) . They
were challenged with 106/ml E. coli-Hly- in the buffer medium . Total amounts of the various AA lipoxygenase products in the perfusate at the
different time intervals after application of the bacteria are given in manomoles . In accompanying in vitro experiments, 5 x 106 PMN were in-
cubated with 106/ml E. coli-Hly- in a buffer volume of 5 ml; total amounts of eicosanoids measured in these studies were corrected (factor 40)
to correspond to the buffer volume in the perfused lung experiments . No eicosanoid liberation was detected in E. coli-Hly+-challenged lungs per-
fused with KHAB, KHAB plus plasma, or KHAB plus PMN; these constellations of buffer fluid have thus been omitted from the table. Similarly,
in vitro incubation ofPMN elicited AA lipooxygenase product generation only in the presence of plasma . 20-OH-LTB4 and 20-COOH-LTB4 are
comprised as w oxidation products of LTB4 The LTA4 hydrolysis products include the 5,6-diastereomeric pair of LTB4 , both nonenzymatically
formed 5,6-diHETEs . Each point represents mean ± SEM of four independent experiments .
noted to induce rapid leukotriene generation (16) . The total
amount of AA lipoxygenase products was -8-10 nmol in
those experiments, and the profile of metabolites corresponded
well to that evoked by infusion ofviable hemolysin-forming
E. coli in the present investigation. A more protracted time
course (plateau after 30-60 min) and lower total amounts
of products (ti3 nmol), noted in thecurrent study, are readily
explainedby the retarded liberation of the exotoxin from the
bacteria and by the lower maximum hemolysin concentra-
tions achieved (-135 ng/ml at the highest E. coli-Hly+ con-
tents used) . The complete absence ofIT release in lungs chal-
lenged with isogenic E. coli-secreting functionally inactive
hemolysin clearly indicates that the bacterial exotoxin rep-
resents the causative agent of inflammatory lipid mediator
induction and excludes a predominant role of bacterial LPS
underthe present conditions. This is in line with thepreceding
study, in whichpurified hemolysin with afar-reaching reduc-
tion in endotoxin content was used . In thepresence of plasma,
no diminution ofE . coli-Hly+-evoked eicosanoid generation
was noted. This finding is noteworthy in view of the hemo-
lysin-inactivating capacity of naturally occurring antibodies
andlipoproteins (14) . It supports the notion that rapid toxin
binding to target cells competes with toxin neutralization .
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Furthermore, it is conceivable that direct transfer of the exo-
toxin from cell-adherent bacteria occurs. In such a "hidden
microenvironment" plasma inactivators might be virtually
ineffective .
Granulocytes are extremely susceptible to attack by E. coli
hemolysin (14, 37-40), and exotoxin-induced leukotriene
generation in these cells has been previously observed (41) .
We found that thetoxin-provoked profile oflipoxygenase prod-
ucts corresponded to that ofcalcium ionophore-exposedneu-
trophils (24, 35, 36, 42). Via the 5-lipoxygenase pathway,
a hydroperoxy intermediate (5-HPETE), and subsequently
the 5,6-epoxide LTA4 , are formed, the latter being converted
to LTB4 as the major enzymatic secretion product . Re-
uptake ofLTB4 ultimately results in the appearance of its to
oxidation products (36, 42, 43). Diverging from this pathway,
5-HPETE is metabolized to 5-HETE, and "excessive" LTA4
is directly released into the extracellular space (44) . In aqueous
medium, this unstableIT intermediate undergoes rapid nonen-
zymatic hydrolysis with a half-time of only a few seconds
(45), resulting in the appearance offour nonenzymatic degra-
dation products (diastereomeric pairs of6-trans-LTB4 and 5,6-
DiHETE) . In theabsenceofplasma,PMN eicosanoid gener-
ation was elicited only by theE. coli strain forming active
Hemolysin-Forming Escherichia coli and Lung Leukotriene Generation
Table 4. Eicosanoid Formation Evoked by Inactive Hemolysin.forming E . coli in the Presence ofPlasma and PMN
Variable Protocol 10 min 20 min
Amount after interval
30 min
of.
60 min 90 min
LTB4 PMN + Pla 0.36 ± 0.09 0.93 ± 0.24 1 .12 ± 0.26 0.44 ± 0.11 0.23 ± 0.06
Lu + PMN + Pla <0.1 0.54 ± 0.18 1 .22 ± 0.41 0.64 ± 0.19 0.33 ± 0.09
20-ox-LTB4 PMN + Pla <0.1 0.41 ± 0.07 0.89 ± 0.25 1.12 ± 0.34 0.98 ± 0.29
Lu + PMN + Pla <0 .1 0.39 ± 0.13 0.95 ± 0.34 1.85 ± 0.49 2 .23 ± 0.80
LTA4 PMN + Pla <0 .1 <0.1 <0.1 <0 .1 <0.1
hydrolysis Lu + PMN + Pla <0 .1 <0.1 <0 .1 <0.1 <0.1
5-HETE PMN + Pla <0.15 0.24 ± 0.10 <0.15 <0.15 <0.15
Lu + PMN + Pla <0.15 <0.15 <0.15 <0.15 <0.15
LTC4 PMN + Pla <0.2 <0.2 <0.2 <0.2 <0.2
Lu + PMN + Pla 0.31 ± 0.13 0.91 ± 0.34 <0.2 0.35 ± 0.09 <0.2
LTE4 PMN + Pla <0.2 <0.2 <0.2 <0.2 <0.2
Lu + PMN + Pla 0.38 ± 0.11 0.99 ± 0 .34 1.61 ± 0.43 1 .58 ± 0.54 2.59 ± 0.71hemolysin . Previous investigations, using different channel-
forming bacterial protein toxins in subcytolytic concentra-
tions, have suggested a central role of transmembrane cal-
cium flux through toxin-created pores in triggering lipid
mediator generation (20, 46-49) . Surprisingly, the E. coli-
Hly+-evoked AA lipoxygenase metabolism was even aug-
mented in the presence of plasma . However, under these cir-
cumstances, moderate PMN eicosanoid generation was also
elicited by theE. coli strain producing inactive toxin . These
findings suggest an opsonizing function of plasma, causing
enhanced bacterial uptake by the PMN ; phagocytosis-related
activation ofAA metabolism is well known . Though phago-
cytosis was not directly measured in the present study, random
microscopical examinations indeed revealed PMN uptake
of both E . coli-Hly + and E. coli-Hly- in the presence of
plasma .
Under conditions oflung neutrophil sequestration, hemo-
lysin attack on both microvascular endothelium and infused
(adherent) granulocytes has to be expected . The profile of
AA lipoxygenase products detected under these circumstances
corresponded to that of non-PMN-charged lungs . LTB4
generation was, however, followed by rapid w oxidation of
this compound, reflecting metabolic activity of the infused
granulocytes. The most striking finding was a severalfold in-
crease in the total amounts of the different AA lipoxygenase
products . Related to the data of non-PMN-charged lungs,
the sum of lipoxygenase products was augmented approxi-
mately threefold in the presence ofPMN and approximately
sixfold after preceding application ofboth PMN and plasma
(quantified 90 min afterE . coli-Hly+-challenge) . Related to
the sum of lipoxygenase products evoked inE . coli-Hly+-
exposed PMN in vitro, a three- to fourfold augmentation
was calculated both in the absence and presence of plasma .
Considering the disappearance rates of the different lipox-
ygenase products in the perfused lung model, which may
surpass 50% after a 90-min recirculation (Table 1), this aug-
mentation of product formation is even more apparent . Col-
lectively, these data suggest PMN endothelial cooperativity
in the model of pulmonary leukostasis in response to the E.
coli-Hly+-challenge. PMN-secreted LTA4, whether evoked
by hemolysin attack or, to a minor extent, by phagocytic ac-
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